Gastroenterologie
a hepatologie

Terapeutické monitorovanie infliximabu pri nešpecifických zápalových ochoreniach čreva

Yashar Jalali¹, Anna Krajčovičová ^{Orcid.org  1}, Tibor Hlavatý ^{Orcid.org  1}

+ Pracoviště
¹ 5th Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital Bratislava, Slovak Republic

Souhrn

Antagonisti tumor nekrotizujúceho faktoru α sa v súčasnosti bežne používajú v liečbe stredne ťažkej až ťažkej formy Crohnovej choroby a ulceróznej kolitídy. Približne 50 % pacientov s nešpecifickými zápalovými ochoreniami čreva, ktorí v úvode profitovali z liečby antagonistami tumor nekrotizujúceho faktoru, po čase stratí liečebný účinok. Účinnosť liečby je vysoko závislá od farmakokinetiky a farmakodynamiky. Terapeutické monitorovanie liečiva (TDM – therapeutic drug monitoring), ktoré predstavuje meranie hladiny liečiva ako aj protilátok proti liečivu (ADAb – anti-drug antibodies), je novým prístupom optimalizácie liečby a dosiahnutia najnižšieho rizika straty odpovede. V súčasnosti nie je jasné presná terapeutická hladina, ktorá by zodpovedala klinickej odpovedi. Produkcia ADAb môže viesť k poklesu hladín až neutralizácii liečiva s následnou stratou liečebného účinku. Rovnako môžu ADAb prispieť k infúznym reakciám, tromboembolickým príhodám a sérovej chorobe. Predkladaný článok skúma vývoj TDM pri liečbe IBD. Skúma hlavné tvrdenia o TDM ako aj vývoj ich používania v poslednom období, skúma terapeutické rozmedzie, stratu odpovede a opisuje súčasné trendy v klinickej praxi.

Klíčová slova

biologická terapia, nešpecifické zápalové ochorenia čreva, protilátky proti liečivu, terapeutické monitorovanie liečiva, terapeutické rozmedzie

Celý článek je dostupný po přepnutí na anglickou verzi webové stránky (v pravém horním rohu).

Literatura

1. Colombel JF, Narula N, Peyrin-Biroulet L.  Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017; 152 (2): 351–361. doi: 10.1053/j.gastro.2016.09.046.
2. Vande Casteele N, Feagan BG, Gils A et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014; 16 (4): 378. doi: 10.1007/s11894-014-0378-0.
3. Vande Casteele N, Herfarth H, Katz J et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 2017; 153 (3): 835–857. doi: 10.1053/j.gastro.2017.07.031.
4. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4 (10): 1248–1254.
5. Singh N, Rosenthal CJ, Melmed GY et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20 (10): 1708–1713. doi: 10.1097/MIB.0000000000000137.
6. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15): 1098–1104.
7. Vermeire S, Noman M, Van Assche G et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007; 56 (9): 1226–1231.
8. Pariente B, de Chambrun GP, Krzysiek R et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 18 (7): 1199–1206. doi: 10.1002/ibd.21 839.
9. Feuerstein JD, Nguyen GC, Kupfer SS et al. American Gastroenterological Association  Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 2017; 153 (3): 827–834. doi: 10.1053/ j.gastro.2017.07.032.
10. Papamichael K, Vande Casteele N, Ferrante M et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis 2017; 23 (9): 1510–1515. doi: 10.1097/MIB.0000000000001231.
11. Papamichael K, Gils A, Rutgeerts P et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2014; 21 (1): 182–197. doi: 10.1097/MIB.0000000000000202.
12. Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn‘s disease: a large single centre experience. J Crohns Colitis 2012; 6 (2): 143–153. doi: 10.1016/j.crohns.2011.07.011.
13. Papamichael K, Van Stappen T, Vande Casteele N et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14 (4): 543–549. doi: 10.1016/j.cgh.2015.11. 014.
14. Roblin X, Boschetti G, Duru G et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis 2017; 23 (11): 2048–2053. doi: 10.1097/MIB.0000000000001223.
15. Fay S, Ungar B, Paul S et al. The association between drug levels and endoscopic recurrence in postoperative patients with Crohn‘s disease treated with tumor necrosis factor inhibitors. Inflamm Bowel Dis 2017; 23 (11): 1924–1929. doi: 10.1097/MIB.0000000000001220.
16. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4 (4): 355–366. doi: 10.1016/j.crohns.2010.04.004.
17. Hlavaty T, Krajcovicova A, Letkovsky J et al. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy. Bratis Lek Listy 2016; 117 (4):  205–211.
18. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn‘s disease. N Eng J Med 2003; 348 (7): 601–608.
19. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn‘s disease: a randomized controlled trial. Gastroenterology 2003; 124 (4): 917–924.
20. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (7): 542–553.
21. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn‘s disease. N Eng J Med 2010; 362 (15): 1383–1395. doi: 10.1056/NEJMoa0904 492.
22. Feagan BG, McDonald JW, Panaccione R et al. S1051 methotrexate for the prevention of antibodies to infliximab in patients with Crohn‘s disease. Gastroenterology 2010; 138 (5): S167–S168. doi: 10.1016/S0016-5085 (10) 60767-6.
23. Vande Casteele N, Gils A, Singh S et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108 (6): 962–971. doi: 10.1038/ajg.2013.12.
24. Feagan BG, Singh S, Lockton S et al. 565 Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn‘s disease (CD). Gastroenterology 2012; 142 (5): S114. doi: 10.1016/S0016-5085 (12) 60430-2.
25. Martelli L, Olivera P, Roblin X et al. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol 2017; 52 (1): 19–25. doi: 10.1007/s00535-016-1266-1.
26. Arias MT, Vande Casteele N, Vermeire S et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (3): 531–538. doi: 10.1016/j.cgh.2014.07.055.
27. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59 (1): 49–54. doi: 10.1136/gut.2009.183095.
28. Adedokun OJ, Sandborn WJ, Feagan BG et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014; 147 (6): 1296–1307. doi: 10.1053/j.gastro.2014.08.035.
29. Brandse JF, Mathôt RA, van der Kleij D et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14 (2): 251–258. doi: 10.1016/j.cgh.2015.10.029.
30. Feagan BG, McDonald JW, Panaccione R et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn‘s disease. Gastroenterology 2014; 146 (3): 681–688. doi: 10.1053/j.gastro.2013.11.024.